Cholangiocarcinoma | Norton Healthcare

Indication: Cholangiocarcinoma

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial

Advanced/Metastatic or Inoperable

Drug Study

Principal Investigator: Robert Martin, M.D., PhD
University of Louisville Physicians - Surgical Oncology

Sponsor: QED Therapeutics

Learn more at ClinicalTrials.gov

Email for more information: mary.healey@louisville.edu

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.